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ABSTRACT 
Objective: Ciprofloxacin hydrochloride tablets which are not extended-release will produce non-constant drug levels in the blood. This study aimed 
to overcome this problem by making ciprofloxacin hydrochloride extended-release tablets with a combination of hydroxypropyl methylcellulose 
(HPMC) K100M and hydroxypropyl methylcellulose (HPMC) K4M by a direct compression method. 
Methods: The method in this study consisted of preformulation, formula design, manufacture of ciprofloxacin hydrochloride tablets, tablet print 
mass testing, IPC (In-Process Control) slow-release tablet mass print, IPC (In-Process Control) quality of slow-release tablet preparation, dissolution 
test, and statistical analysis. Preformulation was carried out aiming to determine the physical and chemical properties of active-excipient 
substances based on a certificate of analysis. This was done using a Fourier Transform Infrared (FT-IR) and UV-Vis spectrophotometer. Five kinds of 
ciprofloxacin hydrochloride tablet formulations were made using the direct pressing method with variations in the concentration of HPMC K100M 
and HPMC K4M. The ratio of percentage of HPMC K100M and HPMC K4M were F1 0,5%: 1%, F2 1%: 0,5%, F3 0,75%: 0,75%, F4 1%: 0%, F5 0%: 
3%. Evaluation of tablet preparations (IPC control) included weight uniformity test, size uniformity test, hardness test, and friability test. The 
dissolution test was carried out for 2 h by hydrochloride acid 0,1 N pH 1.2 as (pH of gastric acid). Statistical analysis using Perfect Block Random 
Design (PBRD) method and further testing using the Newman-Keuls test was applied for the data obtained. 
Results: The test results with FTIR showed that ciprofloxacin hydrochloride used compared to ciprofloxacin hydrochloride BPFI is equivalent and 
has a purity index of 0.992739. Determination of the level of the active ingredient ciprofloxacin hydrochloride was carried out by measuring the 
absorbance of a 5 ppm sample solution at a wavelength of 276 nm. The percentage of absorbance of the solution is then calculated and the result 
obtained is 98.87%. The range of levels that have been set is 98%-102%. These test results were under those listed on the certificate of analysis. The 
results of the IPC test in the form of weight uniformity test, size uniformity test, hardness test, friability test, and uniformity of ciprofloxacin 
hydrochloride levels in the preparation, showed all data obtained fulfilling the requirements set by USP 36 convention (2013). The result from 
dissolution tablet test on 30, 60, and 120 min showed the release of active substance on F1 56.00 %, 67.76 %, and 87.57 %. F2 were 53.42 %, 65.16 
%, and 91.44 %. F3 were 59.18 %, 72.15 %, and 91.20 %. F4 were 50.51 %, 70.70 %, and 95.29 %. F5 were 53.75 %, 69.55 %, and 92.05 %. 
Statistical analysis was applied for the data obtained. Dissolution results illustrated the level of active substances dissolved in the dissolution 
medium for 2 h or in other words the dissolution test results indicated the number of active substances from tablets that were released and enter 
the digestive tract and came in contact with body fluids. 
Conclusion: The dissolution test results as a basis of extended-release tablets showed all of the formulae met dissolution requirements of the 
United States Pharmacopeia (USP) 36 convention. 
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INTRODUCTION 
The drug will affect if the drug level in the blood is between the 
minimum effective concentration (MEC) and below the minimum 
toxic concentration (MTC). Medicines given orally are usually given 
three times a day or even more than three times a day to get the 
concentration of drugs in the blood always between MEC and MTC 
so that the effectiveness of the drug takes place continuously. 
Conventional preparations can produce levels of active substances in 
the blood is not constant because it is generally absorbed quickly. 
Non-constant absorption causes the concentration of drugs in the 
blood to decrease. This has an impact on decreased drug 
effectiveness and bacterial resistance so that therapeutic goals are 
not achieved [1, 2].  
Ciprofloxacin hydrochloride is a quinolone antibiotic. About 70% of 
ciprofloxacin hydrochloride is absorbed through the gastrointestinal 
tract. This drug has a fairly short half-life of 3-4 h. Ciprofloxacin has 
an average start of about 0.5-1 hour and the time to reach peak 
concentration is 1-2 h [3, 4]. 
The resistance of anaerobic bacteria to certain classes of antibiotics 
is increasing globally trending vary by geographic region and often 
vary between species [5]. The sensitivity of pseudomonas aeruginosa 
to ciprofloxacin has been reported [6, 7]. Besides, there are also 
cases of resistance to gram-positive bacteria against ciprofloxacin 
including staphylococcus aureus and corynebacterium sp [8, 9]. 
Budayanti conducted a sensitivity test on 47 neisseria gonorrhea 
isolates taken from 13 eye isolates, from 10 urethra isolates and 24 
cervix isolates against several antibiotics that are often used for 
gonorrhea. It was found that n. gonorrhoeae resistance to 
ciprofloxacin was 42% [10]. Resistance can be prevented by 
controlling drug release so that drug concentration in the blood is 
maintained [2]. The extended-release form is designed so that the 
use of a single dose unit presents the release of several drugs 
immediately after use. This preparation can precisely produce the 
desired therapeutic effect gradually and continuously in releasing 
many drugs over an extended period [11]. Extended-release tablets 
can be made using matrix technology. Hydrophilic matrices can 
release 100% active ingredients [12]. When in contact with water, 
the hydrophilic matrix immediately forms a gel layer around the 
tablet [13]. Hydrophilic matrix types include hydroxypropyl 
methylcellulose (HPMC) [14]. The HPMC matrix needs to be 
combined with other types of HPMC to facilitate drug release. 
This study reports the formulation of a ciprofloxacin hydrochloride 
extended-release tablet with a combination of HPMC K100M and 
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HPMC K4M by direct compression method with statistical analysis. It 
was recognized that other researchers have reported using different 
matrices and did not use direct compression [15, 16]. 
MATERIALS AND METHODS 
Materials 
Ciprofloxacin hydrochloride (Merck), hydroxypropyl methylcellulose 
K100M (Sigma-Aldrich), hydroxypropyl methylcellulose K4M (Sigma-
Aldrich), avicel pH102 (Sigma-Aldrich), aerosil (Sigma-Aldrich). All 
chemicals used for the formulation were pharmaceutical grade. 
Equipments: Tablet printing machine (E. Korsch), mesh sifter no. 10, 16, 
20, 40, and 60 (Retsch), analytical scales (Mettler Toledo), calipers 
(Mitutoyo), hardness tester (Erweka type tb-24), powder flow tester, 
friability tester, type dissolution tool 2 (paddle) (SOTAX AG), UV-Vis 
spectrophotometer (SPEC ORD 200), Fourier transform infrared spectra 
(FT-IR) (IRAffinity-1S Shimadzu), syringes, and glassware commonly 
used at the solida preparation and technology laboratory and research 
laboratory, Faculty of Pharmacy, Universitas Padjadjaran. 
Methods 
The method in this study consisted of preformulation, formula 
design, ciprofloxacin hydrochloride tablet making, tablet print mass 
testing, IPC (In-Process Control) slow-release tablet mass print, IPC 
(In-Process Control) quality of slow-release tablet preparation, 
dissolution test, and statistical analysis. 
For preformulation 
Preformulation was carried out aiming to determine the physical 
and chemical properties of active-excipient substances based on a 
certificate of analysis.  
Two types of equipment namely Fourier Transform Infrared (FT-IR), 
the standard method of using FT-IR for determination of the 
functional groups of ciprofloxacin [17, 18] and UV-Vis. 
Spectrophotometer to determine the level of ciprofloxacin was 
applied. The following method was applied for the UV-Vis 
spectrophotometer: The initial procedure that was carried out 
before the determination of the content was to find the maximum 
wavelength of ciprofloxacin hydrochloride, obtained max. 276 nm. A 
standard curve for ciprofloxacin hydrochloride was made. The 
standard curve for ciprofloxacin hydrochloride was made to obtain a 
linear regression equation. The linear regression equation was used 
to determine the determination of levels of active substances in the 
tablet. The 40 ppm standard solution is diluted into 6 
concentrations, namely 2 ppm, 3 ppm, 4 ppm, 5 ppm, 6 ppm, and 7 
ppm. Each standard solution was then measured at the same 
wavelength. Determination of the level of the active ingredient 
ciprofloxacin hydrochloride was carried out by measuring the 
absorbance of a 5 ppm sample solution at a wavelength of 276 nm. 
The percentage of absorbance of the solution is then calculated and 
the result obtained is 98.87%. The range of levels that have been set 
is 98%-102%. These test results were per those listed on the 
certificate of analysis. Another researcher, however, had used HPLC 
to determine of ciprofloxacin in human plasma and its application in 
bioequivalence test [19]. 
Design formula 
Five ciprofloxacin hydrochloride tablet formulations were made 
using the direct pressing method with variations of HPMC K100M 
and HPMC K4M. Table 1 shows the designed formula for extended 
released ciprofloxacin hydrochloride. 
 
Table 1: Designed formula extended released ciprofloxacin hydrochloride tablet 
Compounds (%) Formula 
F1 F2 F3 F4 F5 
Ciprofloxacin hydrochloride 44.769 44.769 44.769 44.769 44.769 
HPMC K100M 0.50 1.00 0.75 1.00 - 
HPMC K4M 1.00 0.50 0.75 - 3.00 
Avicel pH102 52.73 52.73 52.73 53.23 51.23 
Mg stearate 0.77 0.77 0.77 0.77 0.77 
Aerosil  0.23 0.23 0.23 0.23 0.23 
 
Manufacture of extended-release ciprofloxacin hydrochloride 
tablets 
In this study, a formulation of ciprofloxacin hydrochloride extended-
release tablets were formulated. The active ingredient used was 
ciprofloxacin hydrochloride. Ciprofloxacin hydrochloride was used as a 
urinary tract infection drug with a dose of 291 mg per day. Additional 
substances used are microcrystalline cellulose (avicel pH102) which 
functions as a filler-binder, mg stearate as a lubricant, and aerosil as a 
lubricant. The matrix used in this formula as hydroxypropyl 
methylcellulose (HPMC) K100M and K4M. Comparison of the 
concentration of HPMC K100M and HPMC K4M used were F1 0.50%: 
1.00%, F2 1.00%: 0.50%, and F3 0.75%: 0.75%. In F4 a single HPMC 
K100M was used at 1.00%, while in F5 a single HPMC K4M is used at 
3.00%. Details of the composition of each formula can be seen in table 1. 
Ciprofloxacin hydrochloride tablets were prepared using the direct 
pressing method of 200 tablets for each formula. Formula tablets 
were prepared as many as 5 formulas with each containing an active 
substance (ciprofloxacin hydrochloride) of 291 mg as well as 
variations in the concentration of HPMC K100M and HPMC K4M. The 
manufacturing process was utilizing all the ingredients of the tablets 
that were sifted and weighed according to the amount in each 
formula. Then ciprofloxacin hydrochloride was mixed with HPMC 
K100M and/or HPMC K4M, microcrystalline cellulose (avicel), and 
aerosil for 15 min. After that, magnesium stearate is added to the 
mixture and stirred for 1 minute. Then the print mass of the tablet 
was tested. Then punch and die were prepared which could print 
tablets weighing 650 mg and do tablet printing. 
The matrix used could help slow down the release of active 
substances. Avicel pH102 was used as a filler, binder, and shredder 
in the manufacture of tablets. The filler was used to increase the 
mass of the tablet that would be printed when printing the tablet. 
Binder was used to helping the binding process of the outer and 
inner phases. Also, avicel functions as a crushing agent which 
helps to destroy the tablet so that it could increase the solubility of 
drugs in body fluids. Allowed use of avicel was as much as 20%-
90%. The amount of avicel used in each formula was 
approximately 52%. Magnesium stearate was used as a lubricant. 
Lubricants could help increase the flow strength of the granules at 
the time of pressing so that the granules could spread throughout 
the casting so that no blockage occurred. Besides, the function of 
magnesium stearate was to prevent the tablet from adhering to the 
die and punch surface. The level of magnesium stearate allowed as 
a sliding agent was 0.25%-5%. The amount of magnesium stearate 
used in each formula was 0.77%. Aerosil was used as glidan. 
Glidan was used to reduce friction between particles flowing from 
the hopper to the printing chamber (die), thereby improving the 
flow properties of the powder or granule to be compressed and 
would affect the uniformity of the weight of the tablet. The amount 
of glidan allowed was no more than 3.00% of the total formula. 
The total aerosil in each formula used for printing this tablet was 
0.23% [20-23]. 
In-process control (IPC) print mass 
The evaluation of the print mass of the tablet included a flow 
velocity and rest angle test, and a compressibility test. 
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In-process control (IPC) print tablet 
Evaluation of tablet preparations included weight uniformity test, 
size uniformity test, hardness test, and friability test. 
Dissolution test 
The dissolution test used a modification of Fahmy and Abu-
Gharbiehmethod [24]. A total of 8.4 ml of 0.1N HCl (37% w/v) was 
diluted with water up to 1000 ml. Dissolution media were made to 
resemble a stomach with a pH of 1.2. The dissolution test was 
carried out based on the USP 36 convention using type II equipment 
(paddle) on 0.1 N HCl media as much as 900 ml at 37±0.5 °C for 2 h. 
A total of 6 tablets from each formula were put in a container. The 
first step was to take 5 ml of aliquots at the 30th, 60th and 120th 
minutes. Then 5 ml of HCl was put back in each container to replace 
the aliquots taken. This process was carried out for 2 h. Then the 
amount of dissolved ciprofloxacin hydrochloride was determined by 
measuring dissolved ciprofloxacin hydrochloride using UV 
spectrophotometry at a wavelength of 276 nm. Calculation of the 
results of the dissolution test is carried out using the formula:  
 
Statistic analysis 
Statistical analysis for the dissolution test was carried out using the 
perfect random block design (PRBD) method and further testing was 
done with the Newman-Keuls test. 
RESULTS AND DISCUSSION 
Preformulation 
Preformulation was carried out to ensure the active substance used 
as ciprofloxacin hydrochloride following the requirements. 
Test with fourier transform infrared (FT-IR) 
Fourier transform infrared test was performed to confirm the 
functional groups contained in ciprofloxacin hydrochloride by 
comparing to ciprofloxacin hydrochloride BPFI and to see the purity 
index of ciprofloxacin hydrochloride used (fig. 1) 
 
 
Fig. 1: Results of FT-IR test for ciprofloxacin hydrochloride BPFI standard against ciprofloxacin hydrochloride sample, Note: Grayline = 
ciprofloxacin hydrochloride spectrum of the sample, Orange line = BPFI ciprofloxacin hydrochloride spectrum 
 
Data from the spectrum showed that the two substances tested were a 
similar compound. In the range 1600-1500 cm-1 there was a peak that 
indicated the presence of C-N bonds at a frequency of 1273.07 cm-1. In 
the range 1680-1620 cm-1 there was a peak indicating the functional 
group C = C with a frequency of 1624.13 cm-1. In the range 1725-1705 
cm-1 there was a peak that indicated the presence of C = O bonds with 
a frequency of 1709 cm-1. In the range of 3150-2750 cm-1, there was a 
peak indicating an aromatic C-H functional group with a frequency of 
3100.7 cm-1. In the range 3700-3000 cm-1 there was a peak which 
indicated that there was an N-H functional group with a frequency of 
3378.47 cm-1. In the range 3700-3000 cm-1 there was a peak that 
indicated an O-H functional group with a frequency of 3529.88 cm-1 in 
the sample. The sample purity index value was 0.992739. These data 
quite similar to the FTIR result of Sahoo et. al results [25].  
Determination of the concentration of ciprofloxacin 
hydrochloride 
Determination of ciprofloxacin hydrochloride levels using a UV-Vis 
spectrophotometer has been carried out by researchers.  
In-process control (IPC) print mass 
This process was carried out after mixing the active substance and all 
additives. IPC on print mass was done before the tablet printing 
process. This test was carried out to determine the quality of print 
mass powder which could be used to evaluate if there was a problem 
in the printing process and also to determine the quality of the tablet. 
Print mass IPC included flow and angle of rest and compressibility 
tests. The print mass test results can be seen in table 2. 
 
Table 2: Print mass IPC results 
Test F1 F2 F3 F4 F5 
Flow power (g/s) 2.03±0.09 1.89±0.04 2.08±0.33 1.96±0.01 2.17±0.26 
Resting angle (°) 34.95±1.07 35.33±0.85 35.75±1.21 33.95±1.40 36.00±0.43 
Compressibility (%) 34.09±1.96 31.29±2.44 32.64±1.26 32.28±1.93 33.72±5.38 
 Notes: all data representing an average of 3 trials, given as mean±SD 
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Flow test and resting angle are performed to determine the flow 
capacity of the print mass because if the print mass is easy to flow, 
the resulting tablet will have a good uniformity of weight. The nature 
of the flow is said to be good if it has a range of values of 4-10 g/s, 
said to be difficult to flow in the range 1.6-4 g/s, and at values <1.6 
g/s means it is very difficult to flow. A good resting angle value was 
in the range of 25-30 ° and the range of 30-40 ° including in the fairly 
good group [23]. Based on these results, it could be concluded that 
the resting angle of each formula was quite good. 
The compressibility test was done by calculating the value of real 
tangibility and incompressible density through testing with a tap 
density device. The range of good compressibility was around 12-18 
and in the range, 23-35 was poor [12]. The results obtained 
indicated that each formula had a poor compressibility value. Based 
on the test results it could be concluded that the process of 
compressing the print mass was difficult. 
In-process control (IPC) print tablet: The printed tablet IPC 
results can be seen in table 3. 
 
Table 3: Results of IPC print tablets 
Test F1 F2 F3 F4 F5 
Weight uniformity (g) 0.65±0.00 0.64±0.00 0.65±0.00 0.65±0.00 0.64±0.00 
Diameter (mm) 12.03±0.00 12.04±0.00 12.02±0.00 12.02±0.00 12.02±0.00 
Thick (mm) 5.92±0.01 5.93±0.00 5.92±0.01 5.83±0.05 6.43±0.01 
Hardness (N) 113.50±9.74 117.87±9.74 133.62±6.25 140.75±7.78 66.75±5.74 
Friability (%) 0.24±0.00 0.09±0.00 0.36±0.00 0.25±0.00 0.06±0.00 
Content uniformity (%) 92,72±0.01 90,90±0.00 102,80±0.01 92,93±0.00 100,94±0.05 
 Notes: all data representing an average of 3 trials, given as mean±SD 
 
Weight uniformity test 
This test was carried out on 20 tablets taken at random. According 
to Pharmacopoeia Indonesia Edition IV [26], uniformity of weights 
allowed for tablets of more than 300 mg was±5% of the weight of 
tablets. Based on these requirements, extended-release ciprofloxacin 
hydrochloride tablets ought to have weights ranging from 0.6175 g 
to 0.6825 g. The results obtained from this test were all tablets 
tested from each formula have a good weight uniformity because it 
did not deviate from the specified requirements. 
Size uniformity test 
In this test, the five formulas are measured in diameter and 
thickness. The size uniformity requirements were found in the 
Indonesian Pharmacopoeia IV Edition 1995, which was a diameter of 
no more than three times and no less than 4/3 of tablet thickness. 
Based on the data obtained, it could be concluded that the diameter 
and thickness of the tablets from each formula met the requirements 
set by Pharmacopoeia Indonesia Edition IV. 
Hardness test 
Hardness testing of tablets was done by using a hardness tester. The 
results of testing the hardness of tablets from each formula were 
113.50±9.74, 117.87±9.74, 133.62±6.25, 140.75±7.78, and 66.75± 
5.74. This value was greater than the ideal value of hardness, but 
hardness for an extended-release preparation was neither a 
requirement nor an official standard [27].  
Friability test 
The friability test was carried out by weighing as many as 10 tablets 
because the total unit weight of the tablet is 650 mg. After that, the 
tablet was included in the friability test equipment. The results of 
the friability testing of the five formulas showed good value or 
qualify because it was less than one percent, that was, 0.24%, 0.09%, 
0.36%, 0.25%, and 0.06%. Good Friability indicated the tablet could 
withstand minor scratches or damage during storage [20]. 
Uniformity test of ciprofloxacin hydrochloride content in the 
preparation 
This test was carried out to determine the uniformity of the active 
ingredient of ciprofloxacin hydrochloride in the extended-release 
tablet preparation. Uniformity testing of active substances was 
carried out on each tablet from each formula by weighing 10 tablets 
which were crushed one by one and re-weighed one by one. Then 
the absorbance is measured at a wavelength of 276 nm. The results 
of testing the uniformity of the active substance content are in 
formula 1 92.72%, formula 2 90.90%, formula 3 102.80%, formula 4 
92.93%, and formula 5 100.94%. This value meets the USP 36 
convention requirements, ie the levels of each tablet are in the range 
of 90%-110% of the levels listed on the label [28]. 
 
 
Fig. 2: Dissolution profile of ciprofloxacin hydrochloride extended-release tablets 
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Dissolution test 
Dissolution testing was carried out using a dissolution test type 
II (paddle) for 2 h with dissolution media in the form of 0.1 N 
HCl pH 1.2. The use of hydrochloric acid media was to mimic 
gastric fluid. Before dissolution testing was carried out, a 
standard curve was made using pH 1.2 hydrochloric acid as a 
solvent and blank. Making this standard curve was done to 
calculate the dissolution level of the dissolved substance. The 
next step was dissolution testing. Six tablets were taken 
randomly and tested using a paddle-type dissolution test. The 
dissolution test was carried out for 2 h using a medium pH of 1.2. 
The dissolution results are measured. This absorbance was a 
data release of active substances from tablets to dissolution 
media. After that, the levels of each tablet were tested from each 
formula in the form of a percentage (fig. 2). 
Dissolution test results of ciprofloxacin hydrochloride extended-
release tablets obtained in the 30th minute ie in formula 1 showed 
the release of active substances by 56.00%, in formula 2 showed the 
release of active substances was 53.42%, in formula 3 showed the 
release of active substances was 59.18%, formula 4 shows the 
release of active substances by 50.51%, and in formula 5 shows the 
release of active substances by 53.75%. Based on USP 36 convention 
(table 4), at the 30th
  
 minute, tablets must release active substances 
by 40%-65% [28]. 
Table 4: Requirements for dissolution of ciprofloxacin hydrochloride extended-release 
Time (min) Dissolution amount (%) 
30 40-65 
60 Not less than 60 
120 Not less than 80 
 
From the data that has been obtained, each formula met the 
requirements for the release of active substances. It was found that 
dissolution results at the 60th minute, each formula showed a good 
release of active substances. This could be seen from the data from 
each formula that met the requirements of the USP 36 convention 
where the level of release of active substances at the 30th minute 
was not less than 60%. Dissolution data in the 60th minute, for 
example, formula 1, 2,3,4, and 5 showed the release of active 
substances respectively at 67.76%, 65,16%, 72.15%, 70.70%, and 
69.55%. The percentage of levels of release of active substances at 
the 120th
In formula 1, a combination of a matrix with a greater K4M HPMC 
content than the K100M HPMC content resulted in a greater release 
of active substances than formula 2. This Formula 2 contains less 
HPMC K4M compared to HPMC K100M. From these data, it could be 
concluded that the HPMC K4M produced a higher release of active 
substances than the HPMC K100M. The viscosity of HPMC K100M 
was higher than HPMC K4M so it had a slow hydration ability [29]. 
HPMC K4M has a lower viscosity than HPMC K100M which helps 
release the active substance in the early minutes. The dissolution 
test is an in vitro test that is used as a parameter to determine the 
solubility of active substances in the body. The dissolution test 
shows the release of active substances from the tablet when it enters 
the digestive tract and comes in contact with body fluids [30, 31]. 
Based on this description, the dissolution results of extended-release 
ciprofloxacin hydrochloride tablets depicted the levels of active 
substances dissolved in the dissolution medium for 2 h. 
 minute according to USP 36 convention was no less than 
80%. Based on the overall dissolution data that had been obtained, 
an increase in the content of the HPMC matrix could slow the release 
of active substances because when it came in contact with water or 
gastrointestinal fluid hydration and stretching chains would occur so 
that it could form a thick gel layer. Drug release can occur through 
diffusion and or erosion from the matrix [29]. 
Statistic analysis 
Statistical analysis for the dissolution test used the PRBD method 
[32, 33], in which time as a block and HPMC concentration were 
treated, with the following hypothesis:  
H0 = there was no significant dissolution difference between all 
formulas 
H1 = there was a significant dissolution difference between all 
formulas 
Because Farithmetic<Ftable
F3 vs F5 = 74.1814-71.7857 = 2.33957<3.9096 
, then accept H0 and the test results were not 
significant. It could be concluded that there was no significant 
difference in dissolution between all formulas with a confidence 
level of 95%. If further testing is done using the Newman-Keuls test 
[34], it can be seen whether there is a difference between each 
treatment. From the Newman-Keuls range test the following values 
were obtained:  
F3 vs F4 = 74.1814-72.1746 = 2.0068<3.9096 
F3 vs F2 = 74.1814-70.0106 = 4.1708<4.7668 
F3 vs F1 = 74.1814-70.44465 = 3.7349<3.9096 
F4 vs F5 = 72.1746-71.7857 = 0.3889<3.9096 
F4 vs F2 = 72.1746-70.0106 = 2.164<3.9096 
F4 vs F1 = 72.1746-70.44465 = 1.7281<3.9096 
F5 vs F2 = 71.7857-70.0106 = 1.7751<3.9096 
F5 vs F1 = 71.7857-70.4465 = 1.3392<3.9096 
F1 vs F2 = 70.4465-70.0106 = 0.4359<3.9096 
Based on these results, there was no significant difference in the 
dissolution test results of each formula. 
CONCLUSION 
From the results of the study, it could be concluded that the formula 
for the preparation of ciprofloxacin hydrochloride extended-release 
tablets met USP 36 convention requirements. Tablet formulations 
were carried out using a combination of HPMC K100M and HPMC 
K4M concentrations as a polymer matrix. Tablet dissolution test 
results showed that the preparation of formula 1 with a combination 
of concentration of HPMC K100M and HPMC K4M 1.5% (1:2), 
formula 2 with a combination of HPMC K100M concentration and 
HPMC K4M 1.5% (2:1), formula 3 with the combination of HPMC 
K100M concentration and HPMC K4M 1.5% (1:1), formula 4 with 
HPMC K100M concentration of 1%, and formula 5 with HPMC K4M 
concentration of 3% met the dissolution requirements at USP 36 
convention. 
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